viktar的个人主页 - 老虎社区

viktar

viktar

暂无个人介绍

IP属地：未知

85关注

8粉丝

0主题

0勋章

2021-07-30

WoW

抱歉，原内容已删除

2021-07-28

What is next?

抱歉，原内容已删除

2021-07-27

General Motors is interesting idea.

抱歉，原内容已删除

2021-07-26

Tell me your opinion about this news...

US IPO Week Ahead: 17 IPOs are coming<blockquote>未来一周美国IPO：17家IPO即将上市</blockquote>

2021-07-25

Strange

抱歉，原内容已删除

2021-07-24

Thanks

抱歉，原内容已删除

2021-07-24

Thanks

抱歉，原内容已删除

2021-07-22

OMG

抱歉，原内容已删除

2021-07-21

And how long???

抱歉，原内容已删除

2021-07-20

How it will continue

抱歉，原内容已删除

2021-07-19

Oh.. but will Pfizer ever grow?

抱歉，原内容已删除

2021-07-18

Will it do over on Monday?

抱歉，原内容已删除

2021-07-17

Is this the growth end?

抱歉，原内容已删除

2021-07-16

Oh… Didi

抱歉，原内容已删除

2021-07-15

That is 100% true

抱歉，原内容已删除

2021-07-09

That is cool!

抱歉，原内容已删除

2021-07-08

Sad news…

抱歉，原内容已删除

2021-07-05

Hm…

抱歉，原内容已删除

2021-07-04

Dangerous stock, but promising

抱歉，原内容已删除

2021-07-04

3 of them already in portfolio.

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4087130985557480","uuid":"4087130985557480","gmtCreate":1624052864741,"gmtModify":1624071003118,"name":"viktar","pinyin":"viktar","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":85,"tweetSize":35,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":808282324,"gmtCreate":1627595258368,"gmtModify":1631891107251,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"WoW","listText":"WoW","text":"WoW","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/808282324","repostId":"1165497040","repostType":4,"isVote":1,"tweetType":1,"viewCount":1383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803123366,"gmtCreate":1627428846255,"gmtModify":1631891107256,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"What is next?&nbsp;","listText":"What is next?&nbsp;","text":"What is next?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803123366","repostId":"2154991792","repostType":4,"isVote":1,"tweetType":1,"viewCount":1484,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809011445,"gmtCreate":1627339407887,"gmtModify":1631884275789,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"General Motors is interesting idea.","listText":"General Motors is interesting idea.","text":"General Motors is interesting idea.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/809011445","repostId":"2154957883","repostType":4,"isVote":1,"tweetType":1,"viewCount":1420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177569812,"gmtCreate":1627252881936,"gmtModify":1631891107259,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/177569812","repostId":"1118041582","repostType":4,"repost":{"id":"1118041582","kind":"news","pubTimestamp":1627175995,"share":"https://www.laohu8.com/m/news/1118041582?lang=zh_CN&edition=full","pubTime":"2021-07-25 09:19","market":"us","language":"en","title":"US IPO Week Ahead: 17 IPOs are coming<blockquote>未来一周美国IPO：17家IPO即将上市</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118041582","media":"Renaissance Capital","summary":"After another week of record activity, the IPO market is expected to remain hot with 17 IPOs schedul","content":"<p>After another week of record activity, the IPO market is expected to remain hot with 17 IPOs scheduled for the week ahead.</p><p><blockquote>在又一周创纪录的活动之后，IPO市场预计将保持火热，未来一周将有17起IPO。</blockquote></p><p> Long-awaited retail brokerage&nbsp;<b>Robinhood Markets</b>(HOOD) plans to raise $2.2 billion at a $36.8 billion market cap. The company offers a no-commission retail brokerage platform with over 18 million MAUs. Despite triple-digit revenue growth in the 1Q21, the platform is dependent on trading volumes, and the recent retail trading boom may be unsustainable.</p><p><blockquote>期待已久的零售经纪业务<b>罗宾汉市场</b>(HOOD)计划以368亿美元的市值筹集22亿美元。该公司提供无佣金零售经纪平台，月活跃用户数超过1800万。尽管2021年第一季度的收入实现了三位数的增长，但该平台依赖于交易量，最近的零售交易热潮可能难以为继。</blockquote></p><p> Vehicle battery maker&nbsp;<b>Clarios International</b>(BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. The company manufactures low-voltage vehicles batteries globally, stating that it has the number one market position in the Americas and EMEA. Profitable on an EBIT basis, Clarios saw revenue growth accelerate in the 1H FY21 after turning negative in the FY20 due to COVID.</p><p><blockquote>汽车电池制造商<b>Clarios International</b>(BTRY)计划以97亿美元的市值筹集17亿美元。该公司在全球范围内生产低压汽车电池，并表示其在美洲和欧洲、中东和非洲地区拥有第一的市场地位。在息税前利润的基础上，Clarios的收入增长在2020财年因新冠疫情而转为负值后，在2021财年上半年加速。</blockquote></p><p> Altice’s ad-tech platform&nbsp;<b>Teads</b>(TEAD) plans to raise $751 million at a $4.6 billion market cap. Teads operates a cloud-based programmatic digital advertising platform for advertisers and publishers. Profitable with solid growth, Teads provides monetization services to about 3,100 publishers.</p><p><blockquote>Altice的广告技术平台<b>Teads</b>(TEAD)计划以46亿美元的市值筹集7.51亿美元。Teads为广告商和出版商运营一个基于云的程序化数字广告平台。Teads盈利稳健增长，为约3,100家出版商提供货币化服务。</blockquote></p><p> Education software provider&nbsp;<b>PowerSchool Holdings</b>(PWSC) plans to raise $750 million at a $3.7 billion market cap. The company provides an education platform for teachers to manage classroom activities such as collecting work and grading assignments. Serving over 12,000 customers in over 90 countries globally, PowerSchool turned profitable on a net income basis in the 1Q21.</p><p><blockquote>教育软件提供商<b>动力学校控股</b>(PWSC)计划以37亿美元的市值筹集7.5亿美元。该公司为教师提供了一个教育平台，用于管理课堂活动，如收集作业和评分作业。PowerSchool为全球90多个国家的12,000多名客户提供服务，在2021年第一季度实现了净利润盈利。</blockquote></p><p> After withdrawing its IPO attempt in 2018,<b>Dole</b>(DOLE) plans to raise $559 million at a $2.0 billion market cap. This leading fruit and vegetable company offers over 300 products sourced from over 30 countries to over 80 countries globally. Slow growing and profitable, Dole's offering is being made in connection with its merger with Total Produce.</p><p><blockquote>在2018年撤回IPO尝试后，<b>多尔</b>（都乐）计划以20亿美元的市值筹集5.59亿美元。这家领先的水果和蔬菜公司向全球80多个国家提供来自30多个国家的300多种产品。都乐增长缓慢且盈利，其产品是与Total Product合并时推出的。</blockquote></p><p> Language learning platform&nbsp;<b>Duolingo</b>(DUOL) plans to raise $460 million at a $4.1 billion market cap. Duolingo provides an online platform for over 300 million users to learn over 30 new languages. Benefiting from a COVID-related boost in demand, Duolingo posted triple-digit growth in 2020.</p><p><blockquote>语言学习平台<b>多邻国</b>(DUOL)计划以41亿美元的市值筹集4.6亿美元。多邻国为超过3亿用户提供了一个学习30多种新语言的在线平台。受益于与新冠疫情相关的需求增长，多邻国在2020年实现了三位数的增长。</blockquote></p><p> <b>Traeger</b>(COOK) plans to raise $400 million at a $2.2 billion market cap. This company makes premium backyard wood pellet grills with a tech feature, allowing owners to program, monitor, and control their grill through the Traeger app. Traeger is a category leader of the wood pellet grill, growing revenue at a 28% CAGR from 2017 to 2020.</p><p><blockquote><b>特雷格</b>（库克）计划以22亿美元的市值筹集4亿美元。这家公司生产具有技术功能的优质后院木质颗粒烤架，允许业主通过Traeger应用程序对他们的烤架进行编程、监控和控制。Traeger是木质颗粒烤架的类别领导者，从2017年到2020年，收入以28%的CAGR增长。</blockquote></p><p> Israeli anti-fraud firm&nbsp;<b>Riskified</b>(RSKD) plans to raise $333 million at a $3.1 billion market cap. This company provides e-commerce fraud protection for enterprises. Growing but unprofitable, Riskified saw its free cash flow swing positive in the 1Q21.</p><p><blockquote>以色列反欺诈公司<b>风险化</b>(RSKD)计划以31亿美元的市值筹集3.33亿美元。这家公司为企业提供电子商务欺诈保护。Riskified不断增长但尚未盈利，其自由现金流在2021年第一季度上转为正值。</blockquote></p><p> Financial software provider&nbsp;<b>MeridianLink</b>(MLNK) plans to raise $300 million at a $2.1 billion market cap. MeridianLink offers a cloud-based digital lending and account opening platform for mid-market community banks and credit unions. Although business is cyclical, the company saw double-digit organic growth in the FY20 due to strong mortgage activity.</p><p><blockquote>财务软件提供商<b>子午线链接</b>(MLNK)计划以21亿美元的市值筹集3亿美元。MeridianLink为中端市场社区银行和信用合作社提供基于云的数字借贷和开户平台。尽管业务具有周期性，但由于强劲的抵押贷款活动，该公司在2020财年实现了两位数的有机增长。</blockquote></p><p> Smart home integration system&nbsp;<b>Snap One Holdings</b>(SNPO) plans to raise $270 million at a $1.5 billion market cap. This company provides smart home technology products to over 16,000 professional integrators. Snap One has demonstrated solid growth and was profitable on an EBIT basis in the 1Q21.</p><p><blockquote>智能家居集成系统<b>Snap一号控股</b>(SNPO)计划以15亿美元的市值筹集2.7亿美元。该公司为超过16,000家专业集成商提供智能家居技术产品。Snap一号表现出稳健的增长，并在2021年第一季度按息税前利润计算实现盈利。</blockquote></p><p> Specialty funding solutions provider&nbsp;<b>Preston Hollow Community Capital</b>(PHCC) plans to raise $200 million at a $2.3 billion market cap. This company is a market leader in providing specialized impact financing solutions for projects of significant social and economic importance to local communities in the US. It serves a variety of areas, including infrastructure, education, healthcare, and housing.</p><p><blockquote>专业融资解决方案提供商<b>普雷斯顿霍洛社区资本</b>(PHCC)计划以23亿美元的市值筹集2亿美元。该公司是为对美国当地社区具有重大社会和经济重要性的项目提供专业影响力融资解决方案的市场领导者。它服务于各种领域，包括基础设施、教育、医疗保健和住房。</blockquote></p><p> Vaccine biotech&nbsp;<b>Icosavax</b>(ICVX) plans to raise $150 million at a $590 million market cap. This clinical stage biotech is initially focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology. Its most advanced candidate is currently in a Phase 1/2 trial for SARS-CoV-2.</p><p><blockquote>疫苗生物技术<b>Icosavax</b>(ICVX)计划以5.9亿美元的市值筹集1.5亿美元。这一临床阶段的生物技术最初专注于利用其病毒样颗粒平台技术开发针对传染性呼吸道疾病的疫苗。其最先进的候选药物目前正处于新型冠状病毒病的1/2期试验中。</blockquote></p><p> Cancer biotech&nbsp;<b>Candel Therapeutics</b>(CADL) plans to raise $85 million at a $398 million market cap. Candel's most advanced candidate is currently in a Phase 3 trial in combination with prodrug valacyclovir for newly diagnosed localized prostate cancer with an intermediate or high-risk for progression. The company expects to complete enrollment in the 3Q21 with a final data readout in 2024.</p><p><blockquote>癌症生物技术<b>坎德尔治疗公司</b>(CADL)计划以3.98亿美元的市值筹集8500万美元。Candel最先进的候选药物目前正在与前药伐昔洛韦联合治疗新诊断的中度或高风险进展的局限性前列腺癌的3期试验中。该公司预计将在2024年完成2021年第三季度的注册并公布最终数据。</blockquote></p><p></p><p> Rare disease biotech&nbsp;<b>Rallybio</b>(RLYB) plans to raise $81 million at a $465 million market cap. This clinical stage biotech is developing antibody therapies for rare diseases. Its lead program is currently being evaluated to treat fetal and neonatal alloimmune thrombocytopenia in a Phase 1/2 trial.</p><p><blockquote>罕见病生物技术<b>拉利比奥</b>(RLYB)计划以4.65亿美元的市值筹集8100万美元。这一临床阶段的生物技术正在开发罕见疾病的抗体疗法。其主导项目目前正在1/2期试验中评估治疗胎儿和新生儿同种免疫性血小板减少症。</blockquote></p><p> <b>Ocean Biomedical</b>(OCEA) plans to raise $50 million at a $506 million market cap. The company is currently pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed directly or indirectly from Brown University, Stanford University, and Rhode Island Hospital.</p><p><blockquote><b>海洋生物医学</b>(OCEA)计划以5.06亿美元的市值筹集5000万美元。该公司目前正在开展肿瘤学、纤维化、传染病和炎症方面的临床前项目，这些项目已直接或间接获得布朗大学、斯坦福大学和罗德岛医院的许可。</blockquote></p><p> After postponing in November 2020,<b>IN8bio</b>(INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing allogeneic gamma-delta T cell therapies to treat solid tumors. Although gamma-delta T cells could potentially treat solid tumors, the company is very early stage and has dosed a limited number of patients.</p><p><blockquote>2020年11月延期后，<b>IN8bio</b>(INAB)计划以2.15亿美元的市值筹集4400万美元。这家1期生物技术公司正在开发同种异体γ-δ T细胞疗法来治疗实体瘤。尽管γ-δ T细胞有可能治疗实体瘤，但该公司还处于非常早期的阶段，并且仅为有限数量的患者提供了剂量。</blockquote></p><p> Female cancer biotech&nbsp;<b>Context Therapeutics</b>(CNTX) plans to raise $20 million at a $93 million market cap. Context is developing treatments for female cancers, such as breast, ovarian, and endometrial cancer. The company’s lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer, with preliminary results expected in the 2H21 and the 1H22.</p><p><blockquote>女性癌症生物技术<b>情境疗法</b>(CNTX)计划以9300万美元的市值筹集2000万美元。背景是开发女性癌症的治疗方法，如乳腺癌、卵巢癌和子宫内膜癌。该公司的主要候选药物目前正处于卵巢癌和子宫内膜癌的2期试验中，预计将于21年下半年和22年上半年获得初步结果。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4b38a8af5f92621b2633830553616b5d\" tg-width=\"1271\" tg-height=\"702\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/5faec597a337345b21c846808295821d\" tg-width=\"1272\" tg-height=\"676\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/021cc62ff4eaabd0b6a7dee91fc0d63e\" tg-width=\"1270\" tg-height=\"483\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>IPO Market Snapshot</b></p><p><blockquote><b>IPO市场快照</b></blockquote></p><p> The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/22/2021, the Renaissance IPO Index was down 1.0% year-to-date, while the S&amp;P 500 was up 16.3%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 3.0% year-to-date, while the ACWX was up 8.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include EQT Partners and Smoore International.</p><p><blockquote>文艺复兴IPO指数是新上市公司的市值加权篮子。截至2021年7月22日，文艺复兴IPO指数今年迄今下跌1.0%，而标普500上涨16.3%。Renaissance Capital的IPO ETF（纽约证券交易所股票代码：IPO）跟踪该指数，持有的顶级ETF包括Snowflake（SNOW）和Palantir Technologies（PLTR）。Renaissance International IPO指数今年迄今下跌3.0%，而ACWX指数上涨8.1%。Renaissance Capital的国际IPO ETF（纽约证券交易所股票代码：IPOS）跟踪该指数，持有的顶级ETF包括EQT Partners和思摩尔国际。</blockquote></p><p></p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: 17 IPOs are coming<blockquote>未来一周美国IPO：17家IPO即将上市</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: 17 IPOs are coming<blockquote>未来一周美国IPO：17家IPO即将上市</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Renaissance Capital</strong><span class=\"h-time small\">2021-07-25 09:19</span>\n</p>\n</h4>\n</header>\n<article>\n<p>After another week of record activity, the IPO market is expected to remain hot with 17 IPOs scheduled for the week ahead.</p><p><blockquote>在又一周创纪录的活动之后，IPO市场预计将保持火热，未来一周将有17起IPO。</blockquote></p><p> Long-awaited retail brokerage&nbsp;<b>Robinhood Markets</b>(HOOD) plans to raise $2.2 billion at a $36.8 billion market cap. The company offers a no-commission retail brokerage platform with over 18 million MAUs. Despite triple-digit revenue growth in the 1Q21, the platform is dependent on trading volumes, and the recent retail trading boom may be unsustainable.</p><p><blockquote>期待已久的零售经纪业务<b>罗宾汉市场</b>(HOOD)计划以368亿美元的市值筹集22亿美元。该公司提供无佣金零售经纪平台，月活跃用户数超过1800万。尽管2021年第一季度的收入实现了三位数的增长，但该平台依赖于交易量，最近的零售交易热潮可能难以为继。</blockquote></p><p> Vehicle battery maker&nbsp;<b>Clarios International</b>(BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. The company manufactures low-voltage vehicles batteries globally, stating that it has the number one market position in the Americas and EMEA. Profitable on an EBIT basis, Clarios saw revenue growth accelerate in the 1H FY21 after turning negative in the FY20 due to COVID.</p><p><blockquote>汽车电池制造商<b>Clarios International</b>(BTRY)计划以97亿美元的市值筹集17亿美元。该公司在全球范围内生产低压汽车电池，并表示其在美洲和欧洲、中东和非洲地区拥有第一的市场地位。在息税前利润的基础上，Clarios的收入增长在2020财年因新冠疫情而转为负值后，在2021财年上半年加速。</blockquote></p><p> Altice’s ad-tech platform&nbsp;<b>Teads</b>(TEAD) plans to raise $751 million at a $4.6 billion market cap. Teads operates a cloud-based programmatic digital advertising platform for advertisers and publishers. Profitable with solid growth, Teads provides monetization services to about 3,100 publishers.</p><p><blockquote>Altice的广告技术平台<b>Teads</b>(TEAD)计划以46亿美元的市值筹集7.51亿美元。Teads为广告商和出版商运营一个基于云的程序化数字广告平台。Teads盈利稳健增长，为约3,100家出版商提供货币化服务。</blockquote></p><p> Education software provider&nbsp;<b>PowerSchool Holdings</b>(PWSC) plans to raise $750 million at a $3.7 billion market cap. The company provides an education platform for teachers to manage classroom activities such as collecting work and grading assignments. Serving over 12,000 customers in over 90 countries globally, PowerSchool turned profitable on a net income basis in the 1Q21.</p><p><blockquote>教育软件提供商<b>动力学校控股</b>(PWSC)计划以37亿美元的市值筹集7.5亿美元。该公司为教师提供了一个教育平台，用于管理课堂活动，如收集作业和评分作业。PowerSchool为全球90多个国家的12,000多名客户提供服务，在2021年第一季度实现了净利润盈利。</blockquote></p><p> After withdrawing its IPO attempt in 2018,<b>Dole</b>(DOLE) plans to raise $559 million at a $2.0 billion market cap. This leading fruit and vegetable company offers over 300 products sourced from over 30 countries to over 80 countries globally. Slow growing and profitable, Dole's offering is being made in connection with its merger with Total Produce.</p><p><blockquote>在2018年撤回IPO尝试后，<b>多尔</b>（都乐）计划以20亿美元的市值筹集5.59亿美元。这家领先的水果和蔬菜公司向全球80多个国家提供来自30多个国家的300多种产品。都乐增长缓慢且盈利，其产品是与Total Product合并时推出的。</blockquote></p><p> Language learning platform&nbsp;<b>Duolingo</b>(DUOL) plans to raise $460 million at a $4.1 billion market cap. Duolingo provides an online platform for over 300 million users to learn over 30 new languages. Benefiting from a COVID-related boost in demand, Duolingo posted triple-digit growth in 2020.</p><p><blockquote>语言学习平台<b>多邻国</b>(DUOL)计划以41亿美元的市值筹集4.6亿美元。多邻国为超过3亿用户提供了一个学习30多种新语言的在线平台。受益于与新冠疫情相关的需求增长，多邻国在2020年实现了三位数的增长。</blockquote></p><p> <b>Traeger</b>(COOK) plans to raise $400 million at a $2.2 billion market cap. This company makes premium backyard wood pellet grills with a tech feature, allowing owners to program, monitor, and control their grill through the Traeger app. Traeger is a category leader of the wood pellet grill, growing revenue at a 28% CAGR from 2017 to 2020.</p><p><blockquote><b>特雷格</b>（库克）计划以22亿美元的市值筹集4亿美元。这家公司生产具有技术功能的优质后院木质颗粒烤架，允许业主通过Traeger应用程序对他们的烤架进行编程、监控和控制。Traeger是木质颗粒烤架的类别领导者，从2017年到2020年，收入以28%的CAGR增长。</blockquote></p><p> Israeli anti-fraud firm&nbsp;<b>Riskified</b>(RSKD) plans to raise $333 million at a $3.1 billion market cap. This company provides e-commerce fraud protection for enterprises. Growing but unprofitable, Riskified saw its free cash flow swing positive in the 1Q21.</p><p><blockquote>以色列反欺诈公司<b>风险化</b>(RSKD)计划以31亿美元的市值筹集3.33亿美元。这家公司为企业提供电子商务欺诈保护。Riskified不断增长但尚未盈利，其自由现金流在2021年第一季度上转为正值。</blockquote></p><p> Financial software provider&nbsp;<b>MeridianLink</b>(MLNK) plans to raise $300 million at a $2.1 billion market cap. MeridianLink offers a cloud-based digital lending and account opening platform for mid-market community banks and credit unions. Although business is cyclical, the company saw double-digit organic growth in the FY20 due to strong mortgage activity.</p><p><blockquote>财务软件提供商<b>子午线链接</b>(MLNK)计划以21亿美元的市值筹集3亿美元。MeridianLink为中端市场社区银行和信用合作社提供基于云的数字借贷和开户平台。尽管业务具有周期性，但由于强劲的抵押贷款活动，该公司在2020财年实现了两位数的有机增长。</blockquote></p><p> Smart home integration system&nbsp;<b>Snap One Holdings</b>(SNPO) plans to raise $270 million at a $1.5 billion market cap. This company provides smart home technology products to over 16,000 professional integrators. Snap One has demonstrated solid growth and was profitable on an EBIT basis in the 1Q21.</p><p><blockquote>智能家居集成系统<b>Snap一号控股</b>(SNPO)计划以15亿美元的市值筹集2.7亿美元。该公司为超过16,000家专业集成商提供智能家居技术产品。Snap一号表现出稳健的增长，并在2021年第一季度按息税前利润计算实现盈利。</blockquote></p><p> Specialty funding solutions provider&nbsp;<b>Preston Hollow Community Capital</b>(PHCC) plans to raise $200 million at a $2.3 billion market cap. This company is a market leader in providing specialized impact financing solutions for projects of significant social and economic importance to local communities in the US. It serves a variety of areas, including infrastructure, education, healthcare, and housing.</p><p><blockquote>专业融资解决方案提供商<b>普雷斯顿霍洛社区资本</b>(PHCC)计划以23亿美元的市值筹集2亿美元。该公司是为对美国当地社区具有重大社会和经济重要性的项目提供专业影响力融资解决方案的市场领导者。它服务于各种领域，包括基础设施、教育、医疗保健和住房。</blockquote></p><p> Vaccine biotech&nbsp;<b>Icosavax</b>(ICVX) plans to raise $150 million at a $590 million market cap. This clinical stage biotech is initially focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology. Its most advanced candidate is currently in a Phase 1/2 trial for SARS-CoV-2.</p><p><blockquote>疫苗生物技术<b>Icosavax</b>(ICVX)计划以5.9亿美元的市值筹集1.5亿美元。这一临床阶段的生物技术最初专注于利用其病毒样颗粒平台技术开发针对传染性呼吸道疾病的疫苗。其最先进的候选药物目前正处于新型冠状病毒病的1/2期试验中。</blockquote></p><p> Cancer biotech&nbsp;<b>Candel Therapeutics</b>(CADL) plans to raise $85 million at a $398 million market cap. Candel's most advanced candidate is currently in a Phase 3 trial in combination with prodrug valacyclovir for newly diagnosed localized prostate cancer with an intermediate or high-risk for progression. The company expects to complete enrollment in the 3Q21 with a final data readout in 2024.</p><p><blockquote>癌症生物技术<b>坎德尔治疗公司</b>(CADL)计划以3.98亿美元的市值筹集8500万美元。Candel最先进的候选药物目前正在与前药伐昔洛韦联合治疗新诊断的中度或高风险进展的局限性前列腺癌的3期试验中。该公司预计将在2024年完成2021年第三季度的注册并公布最终数据。</blockquote></p><p></p><p> Rare disease biotech&nbsp;<b>Rallybio</b>(RLYB) plans to raise $81 million at a $465 million market cap. This clinical stage biotech is developing antibody therapies for rare diseases. Its lead program is currently being evaluated to treat fetal and neonatal alloimmune thrombocytopenia in a Phase 1/2 trial.</p><p><blockquote>罕见病生物技术<b>拉利比奥</b>(RLYB)计划以4.65亿美元的市值筹集8100万美元。这一临床阶段的生物技术正在开发罕见疾病的抗体疗法。其主导项目目前正在1/2期试验中评估治疗胎儿和新生儿同种免疫性血小板减少症。</blockquote></p><p> <b>Ocean Biomedical</b>(OCEA) plans to raise $50 million at a $506 million market cap. The company is currently pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed directly or indirectly from Brown University, Stanford University, and Rhode Island Hospital.</p><p><blockquote><b>海洋生物医学</b>(OCEA)计划以5.06亿美元的市值筹集5000万美元。该公司目前正在开展肿瘤学、纤维化、传染病和炎症方面的临床前项目，这些项目已直接或间接获得布朗大学、斯坦福大学和罗德岛医院的许可。</blockquote></p><p> After postponing in November 2020,<b>IN8bio</b>(INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing allogeneic gamma-delta T cell therapies to treat solid tumors. Although gamma-delta T cells could potentially treat solid tumors, the company is very early stage and has dosed a limited number of patients.</p><p><blockquote>2020年11月延期后，<b>IN8bio</b>(INAB)计划以2.15亿美元的市值筹集4400万美元。这家1期生物技术公司正在开发同种异体γ-δ T细胞疗法来治疗实体瘤。尽管γ-δ T细胞有可能治疗实体瘤，但该公司还处于非常早期的阶段，并且仅为有限数量的患者提供了剂量。</blockquote></p><p> Female cancer biotech&nbsp;<b>Context Therapeutics</b>(CNTX) plans to raise $20 million at a $93 million market cap. Context is developing treatments for female cancers, such as breast, ovarian, and endometrial cancer. The company’s lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer, with preliminary results expected in the 2H21 and the 1H22.</p><p><blockquote>女性癌症生物技术<b>情境疗法</b>(CNTX)计划以9300万美元的市值筹集2000万美元。背景是开发女性癌症的治疗方法，如乳腺癌、卵巢癌和子宫内膜癌。该公司的主要候选药物目前正处于卵巢癌和子宫内膜癌的2期试验中，预计将于21年下半年和22年上半年获得初步结果。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4b38a8af5f92621b2633830553616b5d\" tg-width=\"1271\" tg-height=\"702\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/5faec597a337345b21c846808295821d\" tg-width=\"1272\" tg-height=\"676\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/021cc62ff4eaabd0b6a7dee91fc0d63e\" tg-width=\"1270\" tg-height=\"483\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>IPO Market Snapshot</b></p><p><blockquote><b>IPO市场快照</b></blockquote></p><p> The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/22/2021, the Renaissance IPO Index was down 1.0% year-to-date, while the S&amp;P 500 was up 16.3%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 3.0% year-to-date, while the ACWX was up 8.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include EQT Partners and Smoore International.</p><p><blockquote>文艺复兴IPO指数是新上市公司的市值加权篮子。截至2021年7月22日，文艺复兴IPO指数今年迄今下跌1.0%，而标普500上涨16.3%。Renaissance Capital的IPO ETF（纽约证券交易所股票代码：IPO）跟踪该指数，持有的顶级ETF包括Snowflake（SNOW）和Palantir Technologies（PLTR）。Renaissance International IPO指数今年迄今下跌3.0%，而ACWX指数上涨8.1%。Renaissance Capital的国际IPO ETF（纽约证券交易所股票代码：IPOS）跟踪该指数，持有的顶级ETF包括EQT Partners和思摩尔国际。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/84600/US-IPO-Week-Ahead-Robinhood%E2%80%99s-billion-dollar-deal-headlines-a-17-IPO-week\">Renaissance Capital</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COOK":"Traeger Inc. (TGPX Holdings I LLC)",".DJI":"道琼斯","RSKD":"Riskified Ltd.","CADLF":"CADELER AS","DOLE":"都乐食品",".SPX":"S&P 500 Index","PWSC":"PowerSchool Holdings, Inc.","TEAD":"Teads Holding","HOOD":"Robinhood","DUOL":"多邻国","FEOVF":"Oceanic Iron Ore Corp.","SNPO":"Snap One Holdings Corp.",".IXIC":"NASDAQ Composite","CNTX":"Context Therapeutics Inc.","INAB":"IN8bio, Inc.","RLYB":"Rallybio Corp.","ICVX":"Icosavax, Inc.","MLNK":"MeridianLink, Inc. (ex-Project Angel Parent, LLC)"},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/84600/US-IPO-Week-Ahead-Robinhood%E2%80%99s-billion-dollar-deal-headlines-a-17-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118041582","content_text":"After another week of record activity, the IPO market is expected to remain hot with 17 IPOs scheduled for the week ahead.\nLong-awaited retail brokerage Robinhood Markets(HOOD) plans to raise $2.2 billion at a $36.8 billion market cap. The company offers a no-commission retail brokerage platform with over 18 million MAUs. Despite triple-digit revenue growth in the 1Q21, the platform is dependent on trading volumes, and the recent retail trading boom may be unsustainable.\nVehicle battery maker Clarios International(BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. The company manufactures low-voltage vehicles batteries globally, stating that it has the number one market position in the Americas and EMEA. Profitable on an EBIT basis, Clarios saw revenue growth accelerate in the 1H FY21 after turning negative in the FY20 due to COVID.\nAltice’s ad-tech platform Teads(TEAD) plans to raise $751 million at a $4.6 billion market cap. Teads operates a cloud-based programmatic digital advertising platform for advertisers and publishers. Profitable with solid growth, Teads provides monetization services to about 3,100 publishers.\nEducation software provider PowerSchool Holdings(PWSC) plans to raise $750 million at a $3.7 billion market cap. The company provides an education platform for teachers to manage classroom activities such as collecting work and grading assignments. Serving over 12,000 customers in over 90 countries globally, PowerSchool turned profitable on a net income basis in the 1Q21.\nAfter withdrawing its IPO attempt in 2018,Dole(DOLE) plans to raise $559 million at a $2.0 billion market cap. This leading fruit and vegetable company offers over 300 products sourced from over 30 countries to over 80 countries globally. Slow growing and profitable, Dole's offering is being made in connection with its merger with Total Produce.\nLanguage learning platform Duolingo(DUOL) plans to raise $460 million at a $4.1 billion market cap. Duolingo provides an online platform for over 300 million users to learn over 30 new languages. Benefiting from a COVID-related boost in demand, Duolingo posted triple-digit growth in 2020.\nTraeger(COOK) plans to raise $400 million at a $2.2 billion market cap. This company makes premium backyard wood pellet grills with a tech feature, allowing owners to program, monitor, and control their grill through the Traeger app. Traeger is a category leader of the wood pellet grill, growing revenue at a 28% CAGR from 2017 to 2020.\nIsraeli anti-fraud firm Riskified(RSKD) plans to raise $333 million at a $3.1 billion market cap. This company provides e-commerce fraud protection for enterprises. Growing but unprofitable, Riskified saw its free cash flow swing positive in the 1Q21.\nFinancial software provider MeridianLink(MLNK) plans to raise $300 million at a $2.1 billion market cap. MeridianLink offers a cloud-based digital lending and account opening platform for mid-market community banks and credit unions. Although business is cyclical, the company saw double-digit organic growth in the FY20 due to strong mortgage activity.\nSmart home integration system Snap One Holdings(SNPO) plans to raise $270 million at a $1.5 billion market cap. This company provides smart home technology products to over 16,000 professional integrators. Snap One has demonstrated solid growth and was profitable on an EBIT basis in the 1Q21.\nSpecialty funding solutions provider Preston Hollow Community Capital(PHCC) plans to raise $200 million at a $2.3 billion market cap. This company is a market leader in providing specialized impact financing solutions for projects of significant social and economic importance to local communities in the US. It serves a variety of areas, including infrastructure, education, healthcare, and housing.\nVaccine biotech Icosavax(ICVX) plans to raise $150 million at a $590 million market cap. This clinical stage biotech is initially focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology. Its most advanced candidate is currently in a Phase 1/2 trial for SARS-CoV-2.\nCancer biotech Candel Therapeutics(CADL) plans to raise $85 million at a $398 million market cap. Candel's most advanced candidate is currently in a Phase 3 trial in combination with prodrug valacyclovir for newly diagnosed localized prostate cancer with an intermediate or high-risk for progression. The company expects to complete enrollment in the 3Q21 with a final data readout in 2024.\nRare disease biotech Rallybio(RLYB) plans to raise $81 million at a $465 million market cap. This clinical stage biotech is developing antibody therapies for rare diseases. Its lead program is currently being evaluated to treat fetal and neonatal alloimmune thrombocytopenia in a Phase 1/2 trial.\nOcean Biomedical(OCEA) plans to raise $50 million at a $506 million market cap. The company is currently pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed directly or indirectly from Brown University, Stanford University, and Rhode Island Hospital.\nAfter postponing in November 2020,IN8bio(INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing allogeneic gamma-delta T cell therapies to treat solid tumors. Although gamma-delta T cells could potentially treat solid tumors, the company is very early stage and has dosed a limited number of patients.\nFemale cancer biotech Context Therapeutics(CNTX) plans to raise $20 million at a $93 million market cap. Context is developing treatments for female cancers, such as breast, ovarian, and endometrial cancer. The company’s lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer, with preliminary results expected in the 2H21 and the 1H22.\n\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/22/2021, the Renaissance IPO Index was down 1.0% year-to-date, while the S&P 500 was up 16.3%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 3.0% year-to-date, while the ACWX was up 8.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include EQT Partners and Smoore International.","news_type":1,"symbols_score_info":{"DUOL":0.9,"CADLF":0.9,"RSKD":0.9,"FEOVF":0.9,"SNPO":0.9,"RLYB":0.9,"DOLE":0.9,".SPX":0.9,"ICVX":0.9,"PWSC":0.9,"PHCC":0.9,".IXIC":0.9,"COOK":0.9,"CNTX":0.9,"INAB":0.9,"BTRY":0.9,".DJI":0.9,"HOOD":0.9,"MLNK":0.9,"TEAD":0.9}},"isVote":1,"tweetType":1,"viewCount":1271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177007898,"gmtCreate":1627162706914,"gmtModify":1631891107261,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Strange&nbsp;","listText":"Strange&nbsp;","text":"Strange","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/177007898","repostId":"1109439356","repostType":4,"isVote":1,"tweetType":1,"viewCount":1276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174351459,"gmtCreate":1627081884071,"gmtModify":1631891107265,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/174351459","repostId":"2153751984","repostType":4,"isVote":1,"tweetType":1,"viewCount":1285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174920609,"gmtCreate":1627059712701,"gmtModify":1631891107268,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/174920609","repostId":"2153983997","repostType":4,"isVote":1,"tweetType":1,"viewCount":1680,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176596289,"gmtCreate":1626905439341,"gmtModify":1631891107275,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"OMG","listText":"OMG","text":"OMG","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/176596289","repostId":"1137267771","repostType":4,"isVote":1,"tweetType":1,"viewCount":1730,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178297252,"gmtCreate":1626822820876,"gmtModify":1631891107274,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"And how long???&nbsp;","listText":"And how long???&nbsp;","text":"And how long???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178297252","repostId":"2153924256","repostType":4,"isVote":1,"tweetType":1,"viewCount":857,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171849972,"gmtCreate":1626739005796,"gmtModify":1631891107277,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"How it will continue&nbsp;","listText":"How it will continue&nbsp;","text":"How it will continue","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171849972","repostId":"2152652683","repostType":4,"isVote":1,"tweetType":1,"viewCount":2133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173112946,"gmtCreate":1626645310885,"gmtModify":1631891107278,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Oh.. but will Pfizer ever grow?&nbsp;","listText":"Oh.. but will Pfizer ever grow?&nbsp;","text":"Oh.. but will Pfizer ever grow?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173112946","repostId":"2152168563","repostType":4,"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179519125,"gmtCreate":1626562112167,"gmtModify":1631893390739,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Will it do over on Monday?&nbsp;","listText":"Will it do over on Monday?&nbsp;","text":"Will it do over on Monday?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/179519125","repostId":"1198202103","repostType":4,"isVote":1,"tweetType":1,"viewCount":345,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179887864,"gmtCreate":1626503567258,"gmtModify":1631893390752,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Is this the growth end?&nbsp;","listText":"Is this the growth end?&nbsp;","text":"Is this the growth end?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/179887864","repostId":"1198202103","repostType":4,"isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170819182,"gmtCreate":1626418732346,"gmtModify":1631893390763,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Oh… Didi&nbsp;","listText":"Oh… Didi&nbsp;","text":"Oh… Didi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170819182","repostId":"2151570666","repostType":4,"isVote":1,"tweetType":1,"viewCount":502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147974931,"gmtCreate":1626331456223,"gmtModify":1631893390779,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"That is 100% true&nbsp;","listText":"That is 100% true&nbsp;","text":"That is 100% true","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/147974931","repostId":"1133272849","repostType":4,"isVote":1,"tweetType":1,"viewCount":276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141936976,"gmtCreate":1625831867795,"gmtModify":1631893390788,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"That is cool!&nbsp;","listText":"That is cool!&nbsp;","text":"That is cool!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/141936976","repostId":"2150326912","repostType":4,"isVote":1,"tweetType":1,"viewCount":384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149798269,"gmtCreate":1625747513551,"gmtModify":1631893390799,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Sad news…&nbsp;","listText":"Sad news…&nbsp;","text":"Sad news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/149798269","repostId":"1149000119","repostType":4,"isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155284395,"gmtCreate":1625440610617,"gmtModify":1631893390813,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Hm…","listText":"Hm…","text":"Hm…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/155284395","repostId":"2148807114","repostType":4,"isVote":1,"tweetType":1,"viewCount":189,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152471883,"gmtCreate":1625349410542,"gmtModify":1631893390825,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Dangerous stock, but promising&nbsp;","listText":"Dangerous stock, but promising&nbsp;","text":"Dangerous stock, but promising","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/152471883","repostId":"1130764181","repostType":4,"isVote":1,"tweetType":1,"viewCount":193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152441881,"gmtCreate":1625340172043,"gmtModify":1631893390835,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"3 of them already in portfolio.&nbsp;","listText":"3 of them already in portfolio.&nbsp;","text":"3 of them already in portfolio.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/152441881","repostId":"1140994998","repostType":4,"isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":179519125,"gmtCreate":1626562112167,"gmtModify":1631893390739,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Will it do over on Monday?&nbsp;","listText":"Will it do over on Monday?&nbsp;","text":"Will it do over on Monday?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/179519125","repostId":"1198202103","repostType":4,"isVote":1,"tweetType":1,"viewCount":345,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808282324,"gmtCreate":1627595258368,"gmtModify":1631891107251,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"WoW","listText":"WoW","text":"WoW","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/808282324","repostId":"1165497040","repostType":4,"isVote":1,"tweetType":1,"viewCount":1383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177007898,"gmtCreate":1627162706914,"gmtModify":1631891107261,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Strange&nbsp;","listText":"Strange&nbsp;","text":"Strange","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/177007898","repostId":"1109439356","repostType":4,"isVote":1,"tweetType":1,"viewCount":1276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171849972,"gmtCreate":1626739005796,"gmtModify":1631891107277,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"How it will continue&nbsp;","listText":"How it will continue&nbsp;","text":"How it will continue","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171849972","repostId":"2152652683","repostType":4,"isVote":1,"tweetType":1,"viewCount":2133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156842943,"gmtCreate":1625214061982,"gmtModify":1631893390848,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Great news!!!","listText":"Great news!!!","text":"Great news!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/156842943","repostId":"1190296598","repostType":4,"repost":{"id":"1190296598","kind":"news","pubTimestamp":1625213296,"share":"https://www.laohu8.com/m/news/1190296598?lang=zh_CN&edition=full","pubTime":"2021-07-02 16:08","market":"us","language":"en","title":"J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant<blockquote>强生Covid-19疫苗显示出预防德尔塔变异毒株病的初步迹象</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1190296598","media":"The Wall Street Journal","summary":"Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & J","content":"<p>  Vaccine triggered strong immune response in blood samples from eight vaccinated people.  Johnson &amp; Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.</p><p><blockquote>疫苗在八名接种者的血液样本中引发了强烈的免疫反应。强生公司表示，在一项小型实验室研究中，强生公司的sJNJ0.74%Covid-19疫苗显示出有希望的迹象，可以预防在美国和其他国家传播的德尔塔变异毒株。</blockquote></p><p> In laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&amp;J said Thursday.</p><p><blockquote>强生周四表示，在实验室测试中，该疫苗在八名接种者的血液样本中引发了强烈的免疫反应。</blockquote></p><p> The positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.</p><p><blockquote>积极的表现增加了越来越多的证据，表明目前授权的新冠肺炎疫苗可以预防德尔塔变异毒株病毒，这种病毒似乎比早期的毒株更具传染性。</blockquote></p><p> How well the J&amp;J shot fares against the Delta variant has been closely watched by health authorities around the world.</p><p><blockquote>世界各地卫生当局都在密切关注强生疫苗对德尔塔变异毒株的疗效。</blockquote></p><p> Many countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots fromPfizerInc.PFE1.02%and its partnerBioNTech SEBNTX0.05%and fromModernaInc.MRNA0.06%</p><p><blockquote>许多国家一直依赖供应，特别是因为该疫苗比辉瑞Inc.PFE 1.02%及其合作伙伴BioNTech SEBNTX0.05%和ModernaInc.MRNA 0.06%的疫苗更容易运输、处理和储存</blockquote></p><p> The new findings “reinforce the ability of the Johnson &amp; Johnson Covid-19 vaccine to help protect the health of people globally,” said J&amp;J Chief Scientific Officer Paul Stoffels.</p><p><blockquote>J&amp;J首席科学官Paul Stoffels表示，新发现“增强了强生新冠肺炎疫苗帮助保护全球人民健康的能力”。</blockquote></p><p> J&amp;J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.</p><p><blockquote>强生公司还表示，在另一项研究中，其疫苗产生了针对Covid-19的免疫反应，持续了至少八个月，这是研究人员能够研究疫苗持久性的最长时间。</blockquote></p><p> J&amp;J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.</p><p><blockquote>新泽西州新不伦瑞克的J&amp;J在一份新闻稿中发布了高水平的发现，而不是一项详细的同行评审研究。</blockquote></p><p> The Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries,including the U.S.</p><p><blockquote>德尔塔变异毒株于去年年底首次在印度出现。从那时起，它迅速传播，成为包括美国在内的几个国家最常见的Covid-19病毒株。</blockquote></p><p> The variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.</p><p><blockquote>根据人口基因组学公司Helix OpCo LLC的数据，截至6月27日，该变种约占Covid-19阳性检测样本的40%，该公司收集和分析了来自美国几个州的检测样本。</blockquote></p><p> Vaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.</p><p><blockquote>公共卫生当局表示，接种疫苗是对抗德尔塔变异毒株的最佳防御措施，他们在敦促人们接种疫苗时引用了该毒株构成的威胁。</blockquote></p><p> So far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.</p><p><blockquote>到目前为止，研究表明，各种疫苗似乎对Delta毒株有效，特别是一旦个人完全接种了疫苗，尽管疫苗的保护作用不如对原始病毒的保护作用。</blockquote></p><p> Separate studies in England and Scotland found that vaccines from Pfizer-BioNTech andAstraZenecaPLCoffered substantial protection from the Delta variantagainst severe cases of Covid-19 and hospitalization.</p><p><blockquote>英格兰和苏格兰的单独研究发现，辉瑞-BioNTech和阿斯利康的疫苗对严重的Covid-19病例和住院治疗提供了针对Delta变种的实质性保护。</blockquote></p><p> England’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.</p><p><blockquote>英格兰公共卫生机构表示，对14,000例病例的分析发现，辉瑞-BioNTech疫苗将感染Delta后住院的风险降低了96%。</blockquote></p><p> J&amp;J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.</p><p><blockquote>强生的单剂量注射基于与辉瑞-BioNTech和Moderna疫苗不同的技术，但操作与阿斯利康的类似。</blockquote></p><p> J&amp;J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.</p><p><blockquote>强生的疫苗使用了导致普通感冒的病毒的改良版本，携带遗传指令，教导细胞如何制造从冠状病毒表面伸出的刺突蛋白。</blockquote></p><p> Production of the spike protein, in turn,prompts the immune system to develop molecular defensesagainst the coronavirus.</p><p><blockquote>反过来，刺突蛋白的产生促使免疫系统发展针对冠状病毒的分子防御。</blockquote></p><p> In its large, pivotal study, the J&amp;J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.</p><p><blockquote>在其大型关键研究中，强生疫苗预防Covid-19的有效率为66%，预防严重疾病的有效率为85%。这种疫苗在南非似乎不太有效，现在被称为Beta的变种正在那里传播。</blockquote></p><p> Overall, however, it was highly effective in places where variants were spreading during the trial.</p><p><blockquote>然而，总体而言，它在试验期间变异传播的地方非常有效。</blockquote></p><p> J&amp;J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.</p><p><blockquote>强生表示，其最近的实验室研究发现，德尔塔变异毒株的免疫反应高于贝塔。</blockquote></p><p> The study looked at blood samples from eight people in the J&amp;J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.</p><p><blockquote>该研究观察了强生疫苗三期试验中八人的血液样本。研究发现，注射会引发高水平的中和抗体，这是免疫系统中被认为是对抗病毒最有效的药物。</blockquote></p><p> Data on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&amp;J vaccine.</p><p><blockquote>有关疫苗保护持久性的数据来自波士顿贝斯以色列女执事医疗中心的免疫学家丹·巴鲁奇(Dan Barouch)的另一项小型研究，他帮助开发了强生疫苗。</blockquote></p><p> The study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&amp;J said.</p><p><blockquote>J&amp;J表示，该研究发现，对Covid-19（包括Delta毒株）的强烈中和抗体和其他免疫反应持续了八个月。</blockquote></p><p> The U.S. Food and Drug Administrationauthorized J&amp;J’s shotin February.</p><p><blockquote>美国。美国食品和药物管理局二月份批准了强生的注射。</blockquote></p><p> In April, federal health authorities temporarily recommended pausing use of J&amp;J’s vaccine while they investigated a blood-clotting condition among people who got the shot.</p><p><blockquote>今年4月，联邦卫生当局在调查接种疫苗者的凝血状况时，暂时建议暂停使用强生疫苗。</blockquote></p><p> Theauthorities lifted the pauseshortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.</p><p><blockquote>然而，当局不久后解除了暂停，称疫苗的益处大于风险，并发布了治疗这种罕见疾病的建议。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant<blockquote>强生Covid-19疫苗显示出预防德尔塔变异毒株病的初步迹象</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant<blockquote>强生Covid-19疫苗显示出预防德尔塔变异毒株病的初步迹象</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-07-02 16:08</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  Vaccine triggered strong immune response in blood samples from eight vaccinated people.  Johnson &amp; Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.</p><p><blockquote>疫苗在八名接种者的血液样本中引发了强烈的免疫反应。强生公司表示，在一项小型实验室研究中，强生公司的sJNJ0.74%Covid-19疫苗显示出有希望的迹象，可以预防在美国和其他国家传播的德尔塔变异毒株。</blockquote></p><p> In laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&amp;J said Thursday.</p><p><blockquote>强生周四表示，在实验室测试中，该疫苗在八名接种者的血液样本中引发了强烈的免疫反应。</blockquote></p><p> The positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.</p><p><blockquote>积极的表现增加了越来越多的证据，表明目前授权的新冠肺炎疫苗可以预防德尔塔变异毒株病毒，这种病毒似乎比早期的毒株更具传染性。</blockquote></p><p> How well the J&amp;J shot fares against the Delta variant has been closely watched by health authorities around the world.</p><p><blockquote>世界各地卫生当局都在密切关注强生疫苗对德尔塔变异毒株的疗效。</blockquote></p><p> Many countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots fromPfizerInc.PFE1.02%and its partnerBioNTech SEBNTX0.05%and fromModernaInc.MRNA0.06%</p><p><blockquote>许多国家一直依赖供应，特别是因为该疫苗比辉瑞Inc.PFE 1.02%及其合作伙伴BioNTech SEBNTX0.05%和ModernaInc.MRNA 0.06%的疫苗更容易运输、处理和储存</blockquote></p><p> The new findings “reinforce the ability of the Johnson &amp; Johnson Covid-19 vaccine to help protect the health of people globally,” said J&amp;J Chief Scientific Officer Paul Stoffels.</p><p><blockquote>J&amp;J首席科学官Paul Stoffels表示，新发现“增强了强生新冠肺炎疫苗帮助保护全球人民健康的能力”。</blockquote></p><p> J&amp;J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.</p><p><blockquote>强生公司还表示，在另一项研究中，其疫苗产生了针对Covid-19的免疫反应，持续了至少八个月，这是研究人员能够研究疫苗持久性的最长时间。</blockquote></p><p> J&amp;J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.</p><p><blockquote>新泽西州新不伦瑞克的J&amp;J在一份新闻稿中发布了高水平的发现，而不是一项详细的同行评审研究。</blockquote></p><p> The Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries,including the U.S.</p><p><blockquote>德尔塔变异毒株于去年年底首次在印度出现。从那时起，它迅速传播，成为包括美国在内的几个国家最常见的Covid-19病毒株。</blockquote></p><p> The variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.</p><p><blockquote>根据人口基因组学公司Helix OpCo LLC的数据，截至6月27日，该变种约占Covid-19阳性检测样本的40%，该公司收集和分析了来自美国几个州的检测样本。</blockquote></p><p> Vaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.</p><p><blockquote>公共卫生当局表示，接种疫苗是对抗德尔塔变异毒株的最佳防御措施，他们在敦促人们接种疫苗时引用了该毒株构成的威胁。</blockquote></p><p> So far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.</p><p><blockquote>到目前为止，研究表明，各种疫苗似乎对Delta毒株有效，特别是一旦个人完全接种了疫苗，尽管疫苗的保护作用不如对原始病毒的保护作用。</blockquote></p><p> Separate studies in England and Scotland found that vaccines from Pfizer-BioNTech andAstraZenecaPLCoffered substantial protection from the Delta variantagainst severe cases of Covid-19 and hospitalization.</p><p><blockquote>英格兰和苏格兰的单独研究发现，辉瑞-BioNTech和阿斯利康的疫苗对严重的Covid-19病例和住院治疗提供了针对Delta变种的实质性保护。</blockquote></p><p> England’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.</p><p><blockquote>英格兰公共卫生机构表示，对14,000例病例的分析发现，辉瑞-BioNTech疫苗将感染Delta后住院的风险降低了96%。</blockquote></p><p> J&amp;J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.</p><p><blockquote>强生的单剂量注射基于与辉瑞-BioNTech和Moderna疫苗不同的技术，但操作与阿斯利康的类似。</blockquote></p><p> J&amp;J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.</p><p><blockquote>强生的疫苗使用了导致普通感冒的病毒的改良版本，携带遗传指令，教导细胞如何制造从冠状病毒表面伸出的刺突蛋白。</blockquote></p><p> Production of the spike protein, in turn,prompts the immune system to develop molecular defensesagainst the coronavirus.</p><p><blockquote>反过来，刺突蛋白的产生促使免疫系统发展针对冠状病毒的分子防御。</blockquote></p><p> In its large, pivotal study, the J&amp;J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.</p><p><blockquote>在其大型关键研究中，强生疫苗预防Covid-19的有效率为66%，预防严重疾病的有效率为85%。这种疫苗在南非似乎不太有效，现在被称为Beta的变种正在那里传播。</blockquote></p><p> Overall, however, it was highly effective in places where variants were spreading during the trial.</p><p><blockquote>然而，总体而言，它在试验期间变异传播的地方非常有效。</blockquote></p><p> J&amp;J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.</p><p><blockquote>强生表示，其最近的实验室研究发现，德尔塔变异毒株的免疫反应高于贝塔。</blockquote></p><p> The study looked at blood samples from eight people in the J&amp;J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.</p><p><blockquote>该研究观察了强生疫苗三期试验中八人的血液样本。研究发现，注射会引发高水平的中和抗体，这是免疫系统中被认为是对抗病毒最有效的药物。</blockquote></p><p> Data on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&amp;J vaccine.</p><p><blockquote>有关疫苗保护持久性的数据来自波士顿贝斯以色列女执事医疗中心的免疫学家丹·巴鲁奇(Dan Barouch)的另一项小型研究，他帮助开发了强生疫苗。</blockquote></p><p> The study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&amp;J said.</p><p><blockquote>J&amp;J表示，该研究发现，对Covid-19（包括Delta毒株）的强烈中和抗体和其他免疫反应持续了八个月。</blockquote></p><p> The U.S. Food and Drug Administrationauthorized J&amp;J’s shotin February.</p><p><blockquote>美国。美国食品和药物管理局二月份批准了强生的注射。</blockquote></p><p> In April, federal health authorities temporarily recommended pausing use of J&amp;J’s vaccine while they investigated a blood-clotting condition among people who got the shot.</p><p><blockquote>今年4月，联邦卫生当局在调查接种疫苗者的凝血状况时，暂时建议暂停使用强生疫苗。</blockquote></p><p> Theauthorities lifted the pauseshortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.</p><p><blockquote>然而，当局不久后解除了暂停，称疫苗的益处大于风险，并发布了治疗这种罕见疾病的建议。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190296598","content_text":"Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.\nIn laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&J said Thursday.\nThe positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.\nHow well the J&J shot fares against the Delta variant has been closely watched by health authorities around the world.\nMany countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots fromPfizerInc.PFE1.02%and its partnerBioNTech SEBNTX0.05%and fromModernaInc.MRNA0.06%\nThe new findings “reinforce the ability of the Johnson & Johnson Covid-19 vaccine to help protect the health of people globally,” said J&J Chief Scientific Officer Paul Stoffels.\nJ&J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.\nJ&J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.\nThe Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries,including the U.S.\nThe variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.\nVaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.\nSo far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.\nSeparate studies in England and Scotland found that vaccines from Pfizer-BioNTech andAstraZenecaPLCoffered substantial protection from the Delta variantagainst severe cases of Covid-19 and hospitalization.\nEngland’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.\nJ&J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.\nJ&J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.\nProduction of the spike protein, in turn,prompts the immune system to develop molecular defensesagainst the coronavirus.\nIn its large, pivotal study, the J&J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.\nOverall, however, it was highly effective in places where variants were spreading during the trial.\nJ&J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.\nThe study looked at blood samples from eight people in the J&J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.\nData on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&J vaccine.\nThe study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&J said.\nThe U.S. Food and Drug Administrationauthorized J&J’s shotin February.\nIn April, federal health authorities temporarily recommended pausing use of J&J’s vaccine while they investigated a blood-clotting condition among people who got the shot.\nTheauthorities lifted the pauseshortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":164,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174351459,"gmtCreate":1627081884071,"gmtModify":1631891107265,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/174351459","repostId":"2153751984","repostType":4,"isVote":1,"tweetType":1,"viewCount":1285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179887864,"gmtCreate":1626503567258,"gmtModify":1631893390752,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Is this the growth end?&nbsp;","listText":"Is this the growth end?&nbsp;","text":"Is this the growth end?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/179887864","repostId":"1198202103","repostType":4,"isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141936976,"gmtCreate":1625831867795,"gmtModify":1631893390788,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"That is cool!&nbsp;","listText":"That is cool!&nbsp;","text":"That is cool!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/141936976","repostId":"2150326912","repostType":4,"isVote":1,"tweetType":1,"viewCount":384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809011445,"gmtCreate":1627339407887,"gmtModify":1631884275789,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"General Motors is interesting idea.","listText":"General Motors is interesting idea.","text":"General Motors is interesting idea.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/809011445","repostId":"2154957883","repostType":4,"isVote":1,"tweetType":1,"viewCount":1420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178297252,"gmtCreate":1626822820876,"gmtModify":1631891107274,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"And how long???&nbsp;","listText":"And how long???&nbsp;","text":"And how long???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178297252","repostId":"2153924256","repostType":4,"isVote":1,"tweetType":1,"viewCount":857,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173112946,"gmtCreate":1626645310885,"gmtModify":1631891107278,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Oh.. but will Pfizer ever grow?&nbsp;","listText":"Oh.. but will Pfizer ever grow?&nbsp;","text":"Oh.. but will Pfizer ever grow?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173112946","repostId":"2152168563","repostType":4,"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150272064,"gmtCreate":1624918946758,"gmtModify":1633947165606,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Glad that they are in my portfolio!!! Really nice stock!&nbsp;","listText":"Glad that they are in my portfolio!!! Really nice stock!&nbsp;","text":"Glad that they are in my portfolio!!! Really nice stock!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150272064","repostId":"1124372919","repostType":2,"isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177569812,"gmtCreate":1627252881936,"gmtModify":1631891107259,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/177569812","repostId":"1118041582","repostType":4,"repost":{"id":"1118041582","kind":"news","pubTimestamp":1627175995,"share":"https://www.laohu8.com/m/news/1118041582?lang=zh_CN&edition=full","pubTime":"2021-07-25 09:19","market":"us","language":"en","title":"US IPO Week Ahead: 17 IPOs are coming<blockquote>未来一周美国IPO：17家IPO即将上市</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118041582","media":"Renaissance Capital","summary":"After another week of record activity, the IPO market is expected to remain hot with 17 IPOs schedul","content":"<p>After another week of record activity, the IPO market is expected to remain hot with 17 IPOs scheduled for the week ahead.</p><p><blockquote>在又一周创纪录的活动之后，IPO市场预计将保持火热，未来一周将有17起IPO。</blockquote></p><p> Long-awaited retail brokerage&nbsp;<b>Robinhood Markets</b>(HOOD) plans to raise $2.2 billion at a $36.8 billion market cap. The company offers a no-commission retail brokerage platform with over 18 million MAUs. Despite triple-digit revenue growth in the 1Q21, the platform is dependent on trading volumes, and the recent retail trading boom may be unsustainable.</p><p><blockquote>期待已久的零售经纪业务<b>罗宾汉市场</b>(HOOD)计划以368亿美元的市值筹集22亿美元。该公司提供无佣金零售经纪平台，月活跃用户数超过1800万。尽管2021年第一季度的收入实现了三位数的增长，但该平台依赖于交易量，最近的零售交易热潮可能难以为继。</blockquote></p><p> Vehicle battery maker&nbsp;<b>Clarios International</b>(BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. The company manufactures low-voltage vehicles batteries globally, stating that it has the number one market position in the Americas and EMEA. Profitable on an EBIT basis, Clarios saw revenue growth accelerate in the 1H FY21 after turning negative in the FY20 due to COVID.</p><p><blockquote>汽车电池制造商<b>Clarios International</b>(BTRY)计划以97亿美元的市值筹集17亿美元。该公司在全球范围内生产低压汽车电池，并表示其在美洲和欧洲、中东和非洲地区拥有第一的市场地位。在息税前利润的基础上，Clarios的收入增长在2020财年因新冠疫情而转为负值后，在2021财年上半年加速。</blockquote></p><p> Altice’s ad-tech platform&nbsp;<b>Teads</b>(TEAD) plans to raise $751 million at a $4.6 billion market cap. Teads operates a cloud-based programmatic digital advertising platform for advertisers and publishers. Profitable with solid growth, Teads provides monetization services to about 3,100 publishers.</p><p><blockquote>Altice的广告技术平台<b>Teads</b>(TEAD)计划以46亿美元的市值筹集7.51亿美元。Teads为广告商和出版商运营一个基于云的程序化数字广告平台。Teads盈利稳健增长，为约3,100家出版商提供货币化服务。</blockquote></p><p> Education software provider&nbsp;<b>PowerSchool Holdings</b>(PWSC) plans to raise $750 million at a $3.7 billion market cap. The company provides an education platform for teachers to manage classroom activities such as collecting work and grading assignments. Serving over 12,000 customers in over 90 countries globally, PowerSchool turned profitable on a net income basis in the 1Q21.</p><p><blockquote>教育软件提供商<b>动力学校控股</b>(PWSC)计划以37亿美元的市值筹集7.5亿美元。该公司为教师提供了一个教育平台，用于管理课堂活动，如收集作业和评分作业。PowerSchool为全球90多个国家的12,000多名客户提供服务，在2021年第一季度实现了净利润盈利。</blockquote></p><p> After withdrawing its IPO attempt in 2018,<b>Dole</b>(DOLE) plans to raise $559 million at a $2.0 billion market cap. This leading fruit and vegetable company offers over 300 products sourced from over 30 countries to over 80 countries globally. Slow growing and profitable, Dole's offering is being made in connection with its merger with Total Produce.</p><p><blockquote>在2018年撤回IPO尝试后，<b>多尔</b>（都乐）计划以20亿美元的市值筹集5.59亿美元。这家领先的水果和蔬菜公司向全球80多个国家提供来自30多个国家的300多种产品。都乐增长缓慢且盈利，其产品是与Total Product合并时推出的。</blockquote></p><p> Language learning platform&nbsp;<b>Duolingo</b>(DUOL) plans to raise $460 million at a $4.1 billion market cap. Duolingo provides an online platform for over 300 million users to learn over 30 new languages. Benefiting from a COVID-related boost in demand, Duolingo posted triple-digit growth in 2020.</p><p><blockquote>语言学习平台<b>多邻国</b>(DUOL)计划以41亿美元的市值筹集4.6亿美元。多邻国为超过3亿用户提供了一个学习30多种新语言的在线平台。受益于与新冠疫情相关的需求增长，多邻国在2020年实现了三位数的增长。</blockquote></p><p> <b>Traeger</b>(COOK) plans to raise $400 million at a $2.2 billion market cap. This company makes premium backyard wood pellet grills with a tech feature, allowing owners to program, monitor, and control their grill through the Traeger app. Traeger is a category leader of the wood pellet grill, growing revenue at a 28% CAGR from 2017 to 2020.</p><p><blockquote><b>特雷格</b>（库克）计划以22亿美元的市值筹集4亿美元。这家公司生产具有技术功能的优质后院木质颗粒烤架，允许业主通过Traeger应用程序对他们的烤架进行编程、监控和控制。Traeger是木质颗粒烤架的类别领导者，从2017年到2020年，收入以28%的CAGR增长。</blockquote></p><p> Israeli anti-fraud firm&nbsp;<b>Riskified</b>(RSKD) plans to raise $333 million at a $3.1 billion market cap. This company provides e-commerce fraud protection for enterprises. Growing but unprofitable, Riskified saw its free cash flow swing positive in the 1Q21.</p><p><blockquote>以色列反欺诈公司<b>风险化</b>(RSKD)计划以31亿美元的市值筹集3.33亿美元。这家公司为企业提供电子商务欺诈保护。Riskified不断增长但尚未盈利，其自由现金流在2021年第一季度上转为正值。</blockquote></p><p> Financial software provider&nbsp;<b>MeridianLink</b>(MLNK) plans to raise $300 million at a $2.1 billion market cap. MeridianLink offers a cloud-based digital lending and account opening platform for mid-market community banks and credit unions. Although business is cyclical, the company saw double-digit organic growth in the FY20 due to strong mortgage activity.</p><p><blockquote>财务软件提供商<b>子午线链接</b>(MLNK)计划以21亿美元的市值筹集3亿美元。MeridianLink为中端市场社区银行和信用合作社提供基于云的数字借贷和开户平台。尽管业务具有周期性，但由于强劲的抵押贷款活动，该公司在2020财年实现了两位数的有机增长。</blockquote></p><p> Smart home integration system&nbsp;<b>Snap One Holdings</b>(SNPO) plans to raise $270 million at a $1.5 billion market cap. This company provides smart home technology products to over 16,000 professional integrators. Snap One has demonstrated solid growth and was profitable on an EBIT basis in the 1Q21.</p><p><blockquote>智能家居集成系统<b>Snap一号控股</b>(SNPO)计划以15亿美元的市值筹集2.7亿美元。该公司为超过16,000家专业集成商提供智能家居技术产品。Snap一号表现出稳健的增长，并在2021年第一季度按息税前利润计算实现盈利。</blockquote></p><p> Specialty funding solutions provider&nbsp;<b>Preston Hollow Community Capital</b>(PHCC) plans to raise $200 million at a $2.3 billion market cap. This company is a market leader in providing specialized impact financing solutions for projects of significant social and economic importance to local communities in the US. It serves a variety of areas, including infrastructure, education, healthcare, and housing.</p><p><blockquote>专业融资解决方案提供商<b>普雷斯顿霍洛社区资本</b>(PHCC)计划以23亿美元的市值筹集2亿美元。该公司是为对美国当地社区具有重大社会和经济重要性的项目提供专业影响力融资解决方案的市场领导者。它服务于各种领域，包括基础设施、教育、医疗保健和住房。</blockquote></p><p> Vaccine biotech&nbsp;<b>Icosavax</b>(ICVX) plans to raise $150 million at a $590 million market cap. This clinical stage biotech is initially focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology. Its most advanced candidate is currently in a Phase 1/2 trial for SARS-CoV-2.</p><p><blockquote>疫苗生物技术<b>Icosavax</b>(ICVX)计划以5.9亿美元的市值筹集1.5亿美元。这一临床阶段的生物技术最初专注于利用其病毒样颗粒平台技术开发针对传染性呼吸道疾病的疫苗。其最先进的候选药物目前正处于新型冠状病毒病的1/2期试验中。</blockquote></p><p> Cancer biotech&nbsp;<b>Candel Therapeutics</b>(CADL) plans to raise $85 million at a $398 million market cap. Candel's most advanced candidate is currently in a Phase 3 trial in combination with prodrug valacyclovir for newly diagnosed localized prostate cancer with an intermediate or high-risk for progression. The company expects to complete enrollment in the 3Q21 with a final data readout in 2024.</p><p><blockquote>癌症生物技术<b>坎德尔治疗公司</b>(CADL)计划以3.98亿美元的市值筹集8500万美元。Candel最先进的候选药物目前正在与前药伐昔洛韦联合治疗新诊断的中度或高风险进展的局限性前列腺癌的3期试验中。该公司预计将在2024年完成2021年第三季度的注册并公布最终数据。</blockquote></p><p></p><p> Rare disease biotech&nbsp;<b>Rallybio</b>(RLYB) plans to raise $81 million at a $465 million market cap. This clinical stage biotech is developing antibody therapies for rare diseases. Its lead program is currently being evaluated to treat fetal and neonatal alloimmune thrombocytopenia in a Phase 1/2 trial.</p><p><blockquote>罕见病生物技术<b>拉利比奥</b>(RLYB)计划以4.65亿美元的市值筹集8100万美元。这一临床阶段的生物技术正在开发罕见疾病的抗体疗法。其主导项目目前正在1/2期试验中评估治疗胎儿和新生儿同种免疫性血小板减少症。</blockquote></p><p> <b>Ocean Biomedical</b>(OCEA) plans to raise $50 million at a $506 million market cap. The company is currently pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed directly or indirectly from Brown University, Stanford University, and Rhode Island Hospital.</p><p><blockquote><b>海洋生物医学</b>(OCEA)计划以5.06亿美元的市值筹集5000万美元。该公司目前正在开展肿瘤学、纤维化、传染病和炎症方面的临床前项目，这些项目已直接或间接获得布朗大学、斯坦福大学和罗德岛医院的许可。</blockquote></p><p> After postponing in November 2020,<b>IN8bio</b>(INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing allogeneic gamma-delta T cell therapies to treat solid tumors. Although gamma-delta T cells could potentially treat solid tumors, the company is very early stage and has dosed a limited number of patients.</p><p><blockquote>2020年11月延期后，<b>IN8bio</b>(INAB)计划以2.15亿美元的市值筹集4400万美元。这家1期生物技术公司正在开发同种异体γ-δ T细胞疗法来治疗实体瘤。尽管γ-δ T细胞有可能治疗实体瘤，但该公司还处于非常早期的阶段，并且仅为有限数量的患者提供了剂量。</blockquote></p><p> Female cancer biotech&nbsp;<b>Context Therapeutics</b>(CNTX) plans to raise $20 million at a $93 million market cap. Context is developing treatments for female cancers, such as breast, ovarian, and endometrial cancer. The company’s lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer, with preliminary results expected in the 2H21 and the 1H22.</p><p><blockquote>女性癌症生物技术<b>情境疗法</b>(CNTX)计划以9300万美元的市值筹集2000万美元。背景是开发女性癌症的治疗方法，如乳腺癌、卵巢癌和子宫内膜癌。该公司的主要候选药物目前正处于卵巢癌和子宫内膜癌的2期试验中，预计将于21年下半年和22年上半年获得初步结果。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4b38a8af5f92621b2633830553616b5d\" tg-width=\"1271\" tg-height=\"702\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/5faec597a337345b21c846808295821d\" tg-width=\"1272\" tg-height=\"676\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/021cc62ff4eaabd0b6a7dee91fc0d63e\" tg-width=\"1270\" tg-height=\"483\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>IPO Market Snapshot</b></p><p><blockquote><b>IPO市场快照</b></blockquote></p><p> The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/22/2021, the Renaissance IPO Index was down 1.0% year-to-date, while the S&amp;P 500 was up 16.3%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 3.0% year-to-date, while the ACWX was up 8.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include EQT Partners and Smoore International.</p><p><blockquote>文艺复兴IPO指数是新上市公司的市值加权篮子。截至2021年7月22日，文艺复兴IPO指数今年迄今下跌1.0%，而标普500上涨16.3%。Renaissance Capital的IPO ETF（纽约证券交易所股票代码：IPO）跟踪该指数，持有的顶级ETF包括Snowflake（SNOW）和Palantir Technologies（PLTR）。Renaissance International IPO指数今年迄今下跌3.0%，而ACWX指数上涨8.1%。Renaissance Capital的国际IPO ETF（纽约证券交易所股票代码：IPOS）跟踪该指数，持有的顶级ETF包括EQT Partners和思摩尔国际。</blockquote></p><p></p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: 17 IPOs are coming<blockquote>未来一周美国IPO：17家IPO即将上市</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: 17 IPOs are coming<blockquote>未来一周美国IPO：17家IPO即将上市</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Renaissance Capital</strong><span class=\"h-time small\">2021-07-25 09:19</span>\n</p>\n</h4>\n</header>\n<article>\n<p>After another week of record activity, the IPO market is expected to remain hot with 17 IPOs scheduled for the week ahead.</p><p><blockquote>在又一周创纪录的活动之后，IPO市场预计将保持火热，未来一周将有17起IPO。</blockquote></p><p> Long-awaited retail brokerage&nbsp;<b>Robinhood Markets</b>(HOOD) plans to raise $2.2 billion at a $36.8 billion market cap. The company offers a no-commission retail brokerage platform with over 18 million MAUs. Despite triple-digit revenue growth in the 1Q21, the platform is dependent on trading volumes, and the recent retail trading boom may be unsustainable.</p><p><blockquote>期待已久的零售经纪业务<b>罗宾汉市场</b>(HOOD)计划以368亿美元的市值筹集22亿美元。该公司提供无佣金零售经纪平台，月活跃用户数超过1800万。尽管2021年第一季度的收入实现了三位数的增长，但该平台依赖于交易量，最近的零售交易热潮可能难以为继。</blockquote></p><p> Vehicle battery maker&nbsp;<b>Clarios International</b>(BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. The company manufactures low-voltage vehicles batteries globally, stating that it has the number one market position in the Americas and EMEA. Profitable on an EBIT basis, Clarios saw revenue growth accelerate in the 1H FY21 after turning negative in the FY20 due to COVID.</p><p><blockquote>汽车电池制造商<b>Clarios International</b>(BTRY)计划以97亿美元的市值筹集17亿美元。该公司在全球范围内生产低压汽车电池，并表示其在美洲和欧洲、中东和非洲地区拥有第一的市场地位。在息税前利润的基础上，Clarios的收入增长在2020财年因新冠疫情而转为负值后，在2021财年上半年加速。</blockquote></p><p> Altice’s ad-tech platform&nbsp;<b>Teads</b>(TEAD) plans to raise $751 million at a $4.6 billion market cap. Teads operates a cloud-based programmatic digital advertising platform for advertisers and publishers. Profitable with solid growth, Teads provides monetization services to about 3,100 publishers.</p><p><blockquote>Altice的广告技术平台<b>Teads</b>(TEAD)计划以46亿美元的市值筹集7.51亿美元。Teads为广告商和出版商运营一个基于云的程序化数字广告平台。Teads盈利稳健增长，为约3,100家出版商提供货币化服务。</blockquote></p><p> Education software provider&nbsp;<b>PowerSchool Holdings</b>(PWSC) plans to raise $750 million at a $3.7 billion market cap. The company provides an education platform for teachers to manage classroom activities such as collecting work and grading assignments. Serving over 12,000 customers in over 90 countries globally, PowerSchool turned profitable on a net income basis in the 1Q21.</p><p><blockquote>教育软件提供商<b>动力学校控股</b>(PWSC)计划以37亿美元的市值筹集7.5亿美元。该公司为教师提供了一个教育平台，用于管理课堂活动，如收集作业和评分作业。PowerSchool为全球90多个国家的12,000多名客户提供服务，在2021年第一季度实现了净利润盈利。</blockquote></p><p> After withdrawing its IPO attempt in 2018,<b>Dole</b>(DOLE) plans to raise $559 million at a $2.0 billion market cap. This leading fruit and vegetable company offers over 300 products sourced from over 30 countries to over 80 countries globally. Slow growing and profitable, Dole's offering is being made in connection with its merger with Total Produce.</p><p><blockquote>在2018年撤回IPO尝试后，<b>多尔</b>（都乐）计划以20亿美元的市值筹集5.59亿美元。这家领先的水果和蔬菜公司向全球80多个国家提供来自30多个国家的300多种产品。都乐增长缓慢且盈利，其产品是与Total Product合并时推出的。</blockquote></p><p> Language learning platform&nbsp;<b>Duolingo</b>(DUOL) plans to raise $460 million at a $4.1 billion market cap. Duolingo provides an online platform for over 300 million users to learn over 30 new languages. Benefiting from a COVID-related boost in demand, Duolingo posted triple-digit growth in 2020.</p><p><blockquote>语言学习平台<b>多邻国</b>(DUOL)计划以41亿美元的市值筹集4.6亿美元。多邻国为超过3亿用户提供了一个学习30多种新语言的在线平台。受益于与新冠疫情相关的需求增长，多邻国在2020年实现了三位数的增长。</blockquote></p><p> <b>Traeger</b>(COOK) plans to raise $400 million at a $2.2 billion market cap. This company makes premium backyard wood pellet grills with a tech feature, allowing owners to program, monitor, and control their grill through the Traeger app. Traeger is a category leader of the wood pellet grill, growing revenue at a 28% CAGR from 2017 to 2020.</p><p><blockquote><b>特雷格</b>（库克）计划以22亿美元的市值筹集4亿美元。这家公司生产具有技术功能的优质后院木质颗粒烤架，允许业主通过Traeger应用程序对他们的烤架进行编程、监控和控制。Traeger是木质颗粒烤架的类别领导者，从2017年到2020年，收入以28%的CAGR增长。</blockquote></p><p> Israeli anti-fraud firm&nbsp;<b>Riskified</b>(RSKD) plans to raise $333 million at a $3.1 billion market cap. This company provides e-commerce fraud protection for enterprises. Growing but unprofitable, Riskified saw its free cash flow swing positive in the 1Q21.</p><p><blockquote>以色列反欺诈公司<b>风险化</b>(RSKD)计划以31亿美元的市值筹集3.33亿美元。这家公司为企业提供电子商务欺诈保护。Riskified不断增长但尚未盈利，其自由现金流在2021年第一季度上转为正值。</blockquote></p><p> Financial software provider&nbsp;<b>MeridianLink</b>(MLNK) plans to raise $300 million at a $2.1 billion market cap. MeridianLink offers a cloud-based digital lending and account opening platform for mid-market community banks and credit unions. Although business is cyclical, the company saw double-digit organic growth in the FY20 due to strong mortgage activity.</p><p><blockquote>财务软件提供商<b>子午线链接</b>(MLNK)计划以21亿美元的市值筹集3亿美元。MeridianLink为中端市场社区银行和信用合作社提供基于云的数字借贷和开户平台。尽管业务具有周期性，但由于强劲的抵押贷款活动，该公司在2020财年实现了两位数的有机增长。</blockquote></p><p> Smart home integration system&nbsp;<b>Snap One Holdings</b>(SNPO) plans to raise $270 million at a $1.5 billion market cap. This company provides smart home technology products to over 16,000 professional integrators. Snap One has demonstrated solid growth and was profitable on an EBIT basis in the 1Q21.</p><p><blockquote>智能家居集成系统<b>Snap一号控股</b>(SNPO)计划以15亿美元的市值筹集2.7亿美元。该公司为超过16,000家专业集成商提供智能家居技术产品。Snap一号表现出稳健的增长，并在2021年第一季度按息税前利润计算实现盈利。</blockquote></p><p> Specialty funding solutions provider&nbsp;<b>Preston Hollow Community Capital</b>(PHCC) plans to raise $200 million at a $2.3 billion market cap. This company is a market leader in providing specialized impact financing solutions for projects of significant social and economic importance to local communities in the US. It serves a variety of areas, including infrastructure, education, healthcare, and housing.</p><p><blockquote>专业融资解决方案提供商<b>普雷斯顿霍洛社区资本</b>(PHCC)计划以23亿美元的市值筹集2亿美元。该公司是为对美国当地社区具有重大社会和经济重要性的项目提供专业影响力融资解决方案的市场领导者。它服务于各种领域，包括基础设施、教育、医疗保健和住房。</blockquote></p><p> Vaccine biotech&nbsp;<b>Icosavax</b>(ICVX) plans to raise $150 million at a $590 million market cap. This clinical stage biotech is initially focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology. Its most advanced candidate is currently in a Phase 1/2 trial for SARS-CoV-2.</p><p><blockquote>疫苗生物技术<b>Icosavax</b>(ICVX)计划以5.9亿美元的市值筹集1.5亿美元。这一临床阶段的生物技术最初专注于利用其病毒样颗粒平台技术开发针对传染性呼吸道疾病的疫苗。其最先进的候选药物目前正处于新型冠状病毒病的1/2期试验中。</blockquote></p><p> Cancer biotech&nbsp;<b>Candel Therapeutics</b>(CADL) plans to raise $85 million at a $398 million market cap. Candel's most advanced candidate is currently in a Phase 3 trial in combination with prodrug valacyclovir for newly diagnosed localized prostate cancer with an intermediate or high-risk for progression. The company expects to complete enrollment in the 3Q21 with a final data readout in 2024.</p><p><blockquote>癌症生物技术<b>坎德尔治疗公司</b>(CADL)计划以3.98亿美元的市值筹集8500万美元。Candel最先进的候选药物目前正在与前药伐昔洛韦联合治疗新诊断的中度或高风险进展的局限性前列腺癌的3期试验中。该公司预计将在2024年完成2021年第三季度的注册并公布最终数据。</blockquote></p><p></p><p> Rare disease biotech&nbsp;<b>Rallybio</b>(RLYB) plans to raise $81 million at a $465 million market cap. This clinical stage biotech is developing antibody therapies for rare diseases. Its lead program is currently being evaluated to treat fetal and neonatal alloimmune thrombocytopenia in a Phase 1/2 trial.</p><p><blockquote>罕见病生物技术<b>拉利比奥</b>(RLYB)计划以4.65亿美元的市值筹集8100万美元。这一临床阶段的生物技术正在开发罕见疾病的抗体疗法。其主导项目目前正在1/2期试验中评估治疗胎儿和新生儿同种免疫性血小板减少症。</blockquote></p><p> <b>Ocean Biomedical</b>(OCEA) plans to raise $50 million at a $506 million market cap. The company is currently pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed directly or indirectly from Brown University, Stanford University, and Rhode Island Hospital.</p><p><blockquote><b>海洋生物医学</b>(OCEA)计划以5.06亿美元的市值筹集5000万美元。该公司目前正在开展肿瘤学、纤维化、传染病和炎症方面的临床前项目，这些项目已直接或间接获得布朗大学、斯坦福大学和罗德岛医院的许可。</blockquote></p><p> After postponing in November 2020,<b>IN8bio</b>(INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing allogeneic gamma-delta T cell therapies to treat solid tumors. Although gamma-delta T cells could potentially treat solid tumors, the company is very early stage and has dosed a limited number of patients.</p><p><blockquote>2020年11月延期后，<b>IN8bio</b>(INAB)计划以2.15亿美元的市值筹集4400万美元。这家1期生物技术公司正在开发同种异体γ-δ T细胞疗法来治疗实体瘤。尽管γ-δ T细胞有可能治疗实体瘤，但该公司还处于非常早期的阶段，并且仅为有限数量的患者提供了剂量。</blockquote></p><p> Female cancer biotech&nbsp;<b>Context Therapeutics</b>(CNTX) plans to raise $20 million at a $93 million market cap. Context is developing treatments for female cancers, such as breast, ovarian, and endometrial cancer. The company’s lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer, with preliminary results expected in the 2H21 and the 1H22.</p><p><blockquote>女性癌症生物技术<b>情境疗法</b>(CNTX)计划以9300万美元的市值筹集2000万美元。背景是开发女性癌症的治疗方法，如乳腺癌、卵巢癌和子宫内膜癌。该公司的主要候选药物目前正处于卵巢癌和子宫内膜癌的2期试验中，预计将于21年下半年和22年上半年获得初步结果。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4b38a8af5f92621b2633830553616b5d\" tg-width=\"1271\" tg-height=\"702\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/5faec597a337345b21c846808295821d\" tg-width=\"1272\" tg-height=\"676\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/021cc62ff4eaabd0b6a7dee91fc0d63e\" tg-width=\"1270\" tg-height=\"483\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>IPO Market Snapshot</b></p><p><blockquote><b>IPO市场快照</b></blockquote></p><p> The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/22/2021, the Renaissance IPO Index was down 1.0% year-to-date, while the S&amp;P 500 was up 16.3%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 3.0% year-to-date, while the ACWX was up 8.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include EQT Partners and Smoore International.</p><p><blockquote>文艺复兴IPO指数是新上市公司的市值加权篮子。截至2021年7月22日，文艺复兴IPO指数今年迄今下跌1.0%，而标普500上涨16.3%。Renaissance Capital的IPO ETF（纽约证券交易所股票代码：IPO）跟踪该指数，持有的顶级ETF包括Snowflake（SNOW）和Palantir Technologies（PLTR）。Renaissance International IPO指数今年迄今下跌3.0%，而ACWX指数上涨8.1%。Renaissance Capital的国际IPO ETF（纽约证券交易所股票代码：IPOS）跟踪该指数，持有的顶级ETF包括EQT Partners和思摩尔国际。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/84600/US-IPO-Week-Ahead-Robinhood%E2%80%99s-billion-dollar-deal-headlines-a-17-IPO-week\">Renaissance Capital</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COOK":"Traeger Inc. (TGPX Holdings I LLC)",".DJI":"道琼斯","RSKD":"Riskified Ltd.","CADLF":"CADELER AS","DOLE":"都乐食品",".SPX":"S&P 500 Index","PWSC":"PowerSchool Holdings, Inc.","TEAD":"Teads Holding","HOOD":"Robinhood","DUOL":"多邻国","FEOVF":"Oceanic Iron Ore Corp.","SNPO":"Snap One Holdings Corp.",".IXIC":"NASDAQ Composite","CNTX":"Context Therapeutics Inc.","INAB":"IN8bio, Inc.","RLYB":"Rallybio Corp.","ICVX":"Icosavax, Inc.","MLNK":"MeridianLink, Inc. (ex-Project Angel Parent, LLC)"},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/84600/US-IPO-Week-Ahead-Robinhood%E2%80%99s-billion-dollar-deal-headlines-a-17-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118041582","content_text":"After another week of record activity, the IPO market is expected to remain hot with 17 IPOs scheduled for the week ahead.\nLong-awaited retail brokerage Robinhood Markets(HOOD) plans to raise $2.2 billion at a $36.8 billion market cap. The company offers a no-commission retail brokerage platform with over 18 million MAUs. Despite triple-digit revenue growth in the 1Q21, the platform is dependent on trading volumes, and the recent retail trading boom may be unsustainable.\nVehicle battery maker Clarios International(BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. The company manufactures low-voltage vehicles batteries globally, stating that it has the number one market position in the Americas and EMEA. Profitable on an EBIT basis, Clarios saw revenue growth accelerate in the 1H FY21 after turning negative in the FY20 due to COVID.\nAltice’s ad-tech platform Teads(TEAD) plans to raise $751 million at a $4.6 billion market cap. Teads operates a cloud-based programmatic digital advertising platform for advertisers and publishers. Profitable with solid growth, Teads provides monetization services to about 3,100 publishers.\nEducation software provider PowerSchool Holdings(PWSC) plans to raise $750 million at a $3.7 billion market cap. The company provides an education platform for teachers to manage classroom activities such as collecting work and grading assignments. Serving over 12,000 customers in over 90 countries globally, PowerSchool turned profitable on a net income basis in the 1Q21.\nAfter withdrawing its IPO attempt in 2018,Dole(DOLE) plans to raise $559 million at a $2.0 billion market cap. This leading fruit and vegetable company offers over 300 products sourced from over 30 countries to over 80 countries globally. Slow growing and profitable, Dole's offering is being made in connection with its merger with Total Produce.\nLanguage learning platform Duolingo(DUOL) plans to raise $460 million at a $4.1 billion market cap. Duolingo provides an online platform for over 300 million users to learn over 30 new languages. Benefiting from a COVID-related boost in demand, Duolingo posted triple-digit growth in 2020.\nTraeger(COOK) plans to raise $400 million at a $2.2 billion market cap. This company makes premium backyard wood pellet grills with a tech feature, allowing owners to program, monitor, and control their grill through the Traeger app. Traeger is a category leader of the wood pellet grill, growing revenue at a 28% CAGR from 2017 to 2020.\nIsraeli anti-fraud firm Riskified(RSKD) plans to raise $333 million at a $3.1 billion market cap. This company provides e-commerce fraud protection for enterprises. Growing but unprofitable, Riskified saw its free cash flow swing positive in the 1Q21.\nFinancial software provider MeridianLink(MLNK) plans to raise $300 million at a $2.1 billion market cap. MeridianLink offers a cloud-based digital lending and account opening platform for mid-market community banks and credit unions. Although business is cyclical, the company saw double-digit organic growth in the FY20 due to strong mortgage activity.\nSmart home integration system Snap One Holdings(SNPO) plans to raise $270 million at a $1.5 billion market cap. This company provides smart home technology products to over 16,000 professional integrators. Snap One has demonstrated solid growth and was profitable on an EBIT basis in the 1Q21.\nSpecialty funding solutions provider Preston Hollow Community Capital(PHCC) plans to raise $200 million at a $2.3 billion market cap. This company is a market leader in providing specialized impact financing solutions for projects of significant social and economic importance to local communities in the US. It serves a variety of areas, including infrastructure, education, healthcare, and housing.\nVaccine biotech Icosavax(ICVX) plans to raise $150 million at a $590 million market cap. This clinical stage biotech is initially focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology. Its most advanced candidate is currently in a Phase 1/2 trial for SARS-CoV-2.\nCancer biotech Candel Therapeutics(CADL) plans to raise $85 million at a $398 million market cap. Candel's most advanced candidate is currently in a Phase 3 trial in combination with prodrug valacyclovir for newly diagnosed localized prostate cancer with an intermediate or high-risk for progression. The company expects to complete enrollment in the 3Q21 with a final data readout in 2024.\nRare disease biotech Rallybio(RLYB) plans to raise $81 million at a $465 million market cap. This clinical stage biotech is developing antibody therapies for rare diseases. Its lead program is currently being evaluated to treat fetal and neonatal alloimmune thrombocytopenia in a Phase 1/2 trial.\nOcean Biomedical(OCEA) plans to raise $50 million at a $506 million market cap. The company is currently pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed directly or indirectly from Brown University, Stanford University, and Rhode Island Hospital.\nAfter postponing in November 2020,IN8bio(INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing allogeneic gamma-delta T cell therapies to treat solid tumors. Although gamma-delta T cells could potentially treat solid tumors, the company is very early stage and has dosed a limited number of patients.\nFemale cancer biotech Context Therapeutics(CNTX) plans to raise $20 million at a $93 million market cap. Context is developing treatments for female cancers, such as breast, ovarian, and endometrial cancer. The company’s lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer, with preliminary results expected in the 2H21 and the 1H22.\n\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/22/2021, the Renaissance IPO Index was down 1.0% year-to-date, while the S&P 500 was up 16.3%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 3.0% year-to-date, while the ACWX was up 8.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include EQT Partners and Smoore International.","news_type":1,"symbols_score_info":{"DUOL":0.9,"CADLF":0.9,"RSKD":0.9,"FEOVF":0.9,"SNPO":0.9,"RLYB":0.9,"DOLE":0.9,".SPX":0.9,"ICVX":0.9,"PWSC":0.9,"PHCC":0.9,".IXIC":0.9,"COOK":0.9,"CNTX":0.9,"INAB":0.9,"BTRY":0.9,".DJI":0.9,"HOOD":0.9,"MLNK":0.9,"TEAD":0.9}},"isVote":1,"tweetType":1,"viewCount":1271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176596289,"gmtCreate":1626905439341,"gmtModify":1631891107275,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"OMG","listText":"OMG","text":"OMG","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/176596289","repostId":"1137267771","repostType":4,"isVote":1,"tweetType":1,"viewCount":1730,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152441881,"gmtCreate":1625340172043,"gmtModify":1631893390835,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"3 of them already in portfolio.&nbsp;","listText":"3 of them already in portfolio.&nbsp;","text":"3 of them already in portfolio.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/152441881","repostId":"1140994998","repostType":4,"isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126208257,"gmtCreate":1624572598879,"gmtModify":1634004326896,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Moderna probably yes, but other 2 I don’t understand or it should be tooo long term.&nbsp;","listText":"Moderna probably yes, but other 2 I don’t understand or it should be tooo long term.&nbsp;","text":"Moderna probably yes, but other 2 I don’t understand or it should be tooo long term.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/126208257","repostId":"2145046329","repostType":4,"isVote":1,"tweetType":1,"viewCount":542,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126660226,"gmtCreate":1624562190165,"gmtModify":1634004363259,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Will uranium stocks also grow as result? Or we will all use green power?&nbsp;","listText":"Will uranium stocks also grow as result? Or we will all use green power?&nbsp;","text":"Will uranium stocks also grow as result? Or we will all use green power?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126660226","repostId":"1155360226","repostType":4,"isVote":1,"tweetType":1,"viewCount":230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152471883,"gmtCreate":1625349410542,"gmtModify":1631893390825,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Dangerous stock, but promising&nbsp;","listText":"Dangerous stock, but promising&nbsp;","text":"Dangerous stock, but promising","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/152471883","repostId":"1130764181","repostType":4,"isVote":1,"tweetType":1,"viewCount":193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158890121,"gmtCreate":1625142122263,"gmtModify":1633944358537,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"I own several of them. Nice&nbsp;","listText":"I own several of them. Nice&nbsp;","text":"I own several of them. Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158890121","repostId":"2148840288","repostType":4,"isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150081497,"gmtCreate":1624875349519,"gmtModify":1633947656038,"author":{"id":"4087130985557480","authorId":"4087130985557480","name":"viktar","avatar":"https://static.tigerbbs.com/cefa1ac93e2a54bbead7b08d30201b0b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087130985557480","authorIdStr":"4087130985557480"},"themes":[],"htmlText":"Nice list!&nbsp;","listText":"Nice list!&nbsp;","text":"Nice list!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/150081497","repostId":"1103992527","repostType":4,"isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}